Rapport’s RAP-219, licensed from J&J, hits Phase 2 bipolar mania goal, with registrational trials planned for 2H 2027.

Pfizer halts a Phase 2 ITP trial, Lycia targets a $227M IPO, Jemperli wins rectal cancer approval, plus news on AstraZeneca, ...

Epic launched a prescription marketplace with Amazon Pharmacy, Mark Cuban Cost Plus Drugs, Costco & Eli Lilly, letting ...

Median drug launch prices rose 24% from 2022-2025, net prices up 35%. Only 1 of 26 drugs met value benchmarks, causing $1B+ in excess spending.

Astellas partners with AI Proteins, paying up to $400M, to develop miniprotein therapies using AI. CEO Chris Bahl targets ...

A Massachusetts jury awards former Whitehead scientist David Sabatini $6M in his defamation suit against his accuser, who ...

A health­care as­set and roy­al­ties hold­ing com­pa­ny is bring­ing a long-act­ing oral med­i­cine ap­proach back to life, res­ur­rect­ing a drug de­liv­ery plat­form that had ac­cu­mu­lat­ed more ...

Merck KGaA agrees to buy Silence Therapeutics for $1.3B, adding siRNA drug divesiran, which is headed to Phase 3 in polycythemia vera.

Gilead’s oral α4β7 drug emvistegrast posts 31% UC remission in Ph2 SWIFT, topping Entyvio cross-trial; Phase 3 set for 2027.

ScionxBio signs first deal with Sanofi to screen mRNA candidates via its TERA platform. CEO Adi Gilboa-Geffen declined to ...

At the three-month point, 30.2% of patients treated with ABBV-466 met the primary endpoint of endoscopic remission.

TriGemX Bio, formerly Kallyope, will go public via a $600M SPAC with TCGX, getting $246M to push its Phase 3 migraine drug ...